Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria

Completed

Conditions studied: Malaria

In brief

The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.

Key facts

Study ID

NCT01228344

Run by

Novartis Pharmaceuticals

People needed

324

Starts

2010-05-01

Expected to finish

2015-09-30

Last updated by the study team

2017-04-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the CDC. Malaria may be clinically suspected or confirmed (microscopically, and/or by polymerase chain reaction [PCR], and/or rapid diagnostic test [RDT]).

You may not qualify if…

• NA

Where it is running

• Centers for Disease Control and Prevention,GA — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.